AstraZeneca No-Profit Vaccine Strategy
Dr. Sanjeev Panchal, Country President, AstraZeneca Malaysia
20-Sep-21 08:00
Embed Podcast
You can share this podcast by copying this HTML to your clipboard and pasting into your blog or web page.
Close
The unusual pairing of Oxford university scientists and British-Swedish pharmaceutical giant AstraZeneca led to the not for profit Covid-19 vaccine. Billions of doses have been produced but at cost for how long? And why did this particular vaccine receive such intense public scrutiny? We speak to Dr. Sanjeev Panchal, Country President of AstraZeneca Malaysia to find out.
Image credit: Shutterstock.com
Produced by: Shazana Mokhtar
Presented by: Wong Shou Ning
This and more than 60,000 other podcasts in your hand. Download the all new BFM mobile app.
Categories: Business Analysis, Trends and Forecasts, Markets, Politics, Social Issues, law & legal matters, Investments, Health Policy, Diseases & Conditions, Mental Health, Healthy Living, Fitness, Medical Innovation and Technology, Science
Tags: Covid 19, Pandemic, Vaccinations, Delta, Malaysia, Policy, Healthcare, AstraZeneca, Vaccine Equity,
